Skip to main content
SpringerLink
Log in

The Role of Janus Kinases in Hematopoietic Malignancies

  • Chapter
  • First Online:
Jak-Stat Signaling : From Basics to Disease

Abstract

The Janus family tyrosine kinases are indispensible for cytokine signaling and play a crucial role in blood cell production. However, their excessive activity causes various hematological phenotypes associated with overproduction of terminally differentiated cells and/or blastic transformation. Here we review the somatic mutations in the Janus family kinases and the associated hematological phenotypes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adelaide J et al (2006) A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 20:536–537, England

    Article  PubMed  CAS  Google Scholar 

  • Asnafi V et al (2010) JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br J Haematol 148(1):178–179

    Article  PubMed  Google Scholar 

  • Bacher U et al (2006) A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia. Haematologica 91(6):817–820

    PubMed  CAS  Google Scholar 

  • Bardelli A et al (2003) Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300(5621):949

    Article  PubMed  CAS  Google Scholar 

  • Baxter EJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061

    PubMed  CAS  Google Scholar 

  • Bercovich D et al (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome. Lancet 372:1484–1492, England

    Article  PubMed  CAS  Google Scholar 

  • Bousquet M et al (2005) The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 24:7248–7252. doi:10.1038/sj.onc.1208850, published online 8 August 2005.: England

    Article  PubMed  CAS  Google Scholar 

  • Campbell PJ, Green AR (2006) The myeloproliferative disorders. N Engl J Med 355(23):2452–2466

    Article  PubMed  CAS  Google Scholar 

  • Carron C et al (2000) TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95(12):3891–3899

    PubMed  CAS  Google Scholar 

  • Chen AT, Prchal JT (2010) JAK2 kinase inhibitors and myeloproliferative disorders. Curr Opin Hematol 17(2):110–116

    Article  PubMed  CAS  Google Scholar 

  • Cirmena G et al (2008) A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia. Cancer Genet Cytogenet 183:105–108, 2008 Elsevier Inc.: United States

    Article  PubMed  CAS  Google Scholar 

  • Correa PN, Eskinazi D, Axelrad AA (1994) Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 83(1):99–112

    PubMed  CAS  Google Scholar 

  • Dai CH et al (1991) Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3. J Clin Invest 87(2):391–396

    Article  PubMed  CAS  Google Scholar 

  • Dai CH et al (1992) Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 80(4):891–899

    PubMed  CAS  Google Scholar 

  • Dargent JL et al (2011) Pathology of the bone marrow and spleen in a case of myelodysplastic/myeloproliferative neoplasm associated with t(8;9)(p22;p24) involving PCM1 and JAK2 genes. Eur J Haematol 86(1):87–90

    Article  PubMed  Google Scholar 

  • De Braekeleer E, Ferec C, De Braekeleer M (2009) RUNX1 translocations in malignant hemopathies. Anticancer Res 29(4):1031–1037

    PubMed  Google Scholar 

  • Delhommeau F et al (2007) Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 109(1):71–77

    Article  PubMed  CAS  Google Scholar 

  • dos Santos NR, Ghysdael J (2006) A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia. Leukemia 20:182–185, England

    Article  PubMed  Google Scholar 

  • dos Santos NR et al (2007) Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. Blood 109(9):3972–3981

    Article  PubMed  Google Scholar 

  • Flex E et al (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 205(4):751–758

    Article  PubMed  CAS  Google Scholar 

  • Gaikwad A et al (2009) Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 144:930–932, England

    Article  PubMed  CAS  Google Scholar 

  • Ghoreschi K, Laurence A, O’Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228(1):273–287

    Article  PubMed  CAS  Google Scholar 

  • Goerttler P et al (2005) The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood 106(8):2862–2864

    Article  PubMed  CAS  Google Scholar 

  • Gordon GM et al (2010) Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-gamma. Biochem J 432(2):255–265

    Article  PubMed  CAS  Google Scholar 

  • Greenman C et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446(7132):153–158

    Article  PubMed  CAS  Google Scholar 

  • Griesinger F et al (2005) A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 44(3):329–333

    Article  PubMed  CAS  Google Scholar 

  • Grunebach F et al (2006) Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera. Leukemia 20(12):2210–2211

    Article  PubMed  CAS  Google Scholar 

  • Harrison DA et al (1995) Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J 14(12):2857–2865

    PubMed  CAS  Google Scholar 

  • Hasle H, Clemmensen IH, Mikkelsen M (2000) Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 355:165–169, England

    Article  PubMed  CAS  Google Scholar 

  • Ho JM et al (1999) Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 93(12):4354–4364

    PubMed  CAS  Google Scholar 

  • Hoelbl A et al (2010) Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med 2(3):98–110

    Article  PubMed  CAS  Google Scholar 

  • James C et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144–1148

    Article  PubMed  CAS  Google Scholar 

  • Jamieson CH et al (2006) The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 103(16):6224–6229

    Article  PubMed  CAS  Google Scholar 

  • Jelinek J et al (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106(10):3370–3373

    Article  PubMed  CAS  Google Scholar 

  • Jeong EG et al (2008) Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 14(12):3716–3721

    Article  PubMed  CAS  Google Scholar 

  • Jones AV et al (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41:446–449

    Article  PubMed  CAS  Google Scholar 

  • Kameda T et al (2010) Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. Int J Hematol 92(2):320–325

    Article  PubMed  CAS  Google Scholar 

  • Karow A et al (2008) JAK2 mutations other than V617F: a novel mutation and mini review. Leuk Res 32(2):365–366

    Article  PubMed  CAS  Google Scholar 

  • Kawahara A et al (1995) Critical role of the interleukin 2 (IL-2) receptor gamma-chain-associated Jak3 in the IL-2-induced c-fos and c-myc, but not bcl-2, gene induction. Proc Natl Acad Sci USA 92(19):8724–8728

    Article  PubMed  CAS  Google Scholar 

  • Kearney L et al (2009) Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 113:646–648

    Article  PubMed  CAS  Google Scholar 

  • Kennedy JA et al (2006) Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo. Proc Natl Acad Sci USA 103(45):16930–16935

    Article  PubMed  CAS  Google Scholar 

  • Kilpivaara O et al (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41:455–459

    Article  PubMed  CAS  Google Scholar 

  • Kralovics R et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779–1790

    Article  PubMed  CAS  Google Scholar 

  • Kratz CP et al (2006) Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 20:381–383, England

    Article  PubMed  CAS  Google Scholar 

  • Lacout C et al (2006) JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108(5):1652–1660

    Article  PubMed  CAS  Google Scholar 

  • Lacronique V et al (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278(5341):1309–1312

    Article  PubMed  CAS  Google Scholar 

  • Lai KS et al (1995) A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells. J Biol Chem 270(42):25028–25036

    Article  PubMed  CAS  Google Scholar 

  • Lane SW et al (2008) Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCR-JAK2 fusion. Br J Haematol 142:503, England

    Article  PubMed  Google Scholar 

  • Lee JW et al (2006) The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25(9):1434–1436

    Article  PubMed  CAS  Google Scholar 

  • Levine RL et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387–397

    Article  PubMed  CAS  Google Scholar 

  • Levine RL et al (2006) X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107(10):4139–4141

    Article  PubMed  CAS  Google Scholar 

  • Li Z et al (2007) Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 282(6):3428–3432

    Article  PubMed  CAS  Google Scholar 

  • Lindauer K et al (2001) Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 14(1):27–37

    Article  PubMed  CAS  Google Scholar 

  • Luo H et al (1997) Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol 17(3):1562–1571

    PubMed  CAS  Google Scholar 

  • Ma W et al (2009) Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn 11(1):49–53

    Article  PubMed  CAS  Google Scholar 

  • Ma W et al (2010) JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms. PLoS One 5(8):e12165

    Article  PubMed  Google Scholar 

  • Malinge S et al (2006) Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha. Oncogene 25(25):3589–3597

    Article  PubMed  CAS  Google Scholar 

  • Malinge S et al (2007) Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 109(5):2202–2204

    Article  PubMed  CAS  Google Scholar 

  • Malinge S et al (2008) Activating mutations in human acute megakaryoblastic leukemia. Blood 112(10):4220–4226

    Article  PubMed  CAS  Google Scholar 

  • Mark HF et al (2006) Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene. Exp Mol Pathol 81(3):217–223

    Article  PubMed  CAS  Google Scholar 

  • Migone TS et al (1995) Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269(5220):79–81

    Article  PubMed  CAS  Google Scholar 

  • Minegishi Y et al (2006) Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25(5):745–755

    Article  PubMed  CAS  Google Scholar 

  • Mullighan CG et al (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 106(23):9414–9418

    Article  PubMed  CAS  Google Scholar 

  • Murati A et al (2005) PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 19:1692–1696, England

    Article  PubMed  CAS  Google Scholar 

  • Najfeld V et al (2007) Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms. Exp Hematol 35(11):1668–1676

    Article  PubMed  CAS  Google Scholar 

  • Nebral K et al (2009) Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23(1):134–143

    Article  PubMed  CAS  Google Scholar 

  • Nguyen MH et al (2001) TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3′-kinase/protein kinase B signaling pathway. J Biol Chem 276(35):32704–32713

    Article  PubMed  CAS  Google Scholar 

  • Olcaydu D et al (2009a) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41:450–454

    Article  PubMed  CAS  Google Scholar 

  • Olcaydu D et al (2009b) The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23:1924–1926

    Article  PubMed  CAS  Google Scholar 

  • Pardanani A et al (2008) Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 111(5):2785–2789

    Article  PubMed  CAS  Google Scholar 

  • Peeters P et al (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90(7):2535–2540

    PubMed  CAS  Google Scholar 

  • Poitras JL et al (2008) Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 47(10):884–889

    Article  PubMed  CAS  Google Scholar 

  • Prchal JF, Axelrad AA (1974) Letter: bone-marrow responses in polycythemia vera. N Engl J Med 290(24):1382

    PubMed  CAS  Google Scholar 

  • Reiter A et al (2005) The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 65:2662–2667, United States

    Article  PubMed  CAS  Google Scholar 

  • Royer Y et al (2005) Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem 280(29):27251–27261

    Article  PubMed  CAS  Google Scholar 

  • Saharinen P, Silvennoinen O (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277(49):47954–47963

    Article  PubMed  CAS  Google Scholar 

  • Santos SC et al (2001) Involvement of the NF-kappaB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein. FEBS Lett 497:148–152, Netherlands

    Article  PubMed  CAS  Google Scholar 

  • Schwaller J et al (1998) Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 17(18):5321–5333

    Article  PubMed  CAS  Google Scholar 

  • Schwaller J et al (2000) Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 6:693–704, United States

    Article  PubMed  CAS  Google Scholar 

  • Scott LM et al (2005) The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 106(8):2920–2921

    Article  PubMed  CAS  Google Scholar 

  • Scott LM et al (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356(5):459–468

    Article  PubMed  CAS  Google Scholar 

  • Sozer S et al (2009) Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo. Blood Cells Mol Dis 43(3):304–312

    Article  PubMed  CAS  Google Scholar 

  • Steensma DP et al (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both. Blood 106(4):1207–1209

    Article  PubMed  CAS  Google Scholar 

  • Tefferi A, Vardiman J (2007) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14–22

    Article  PubMed  Google Scholar 

  • Teofili L et al (2011) Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood 117(9):2700–2707

    Article  PubMed  CAS  Google Scholar 

  • Tiedt R et al (2008) Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111(8):3931–3940

    Article  PubMed  CAS  Google Scholar 

  • Tirado CA et al (2010) Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia. Leuk Res 34(12):1674–1676

    Article  PubMed  CAS  Google Scholar 

  • Tortolani PJ et al (1995) Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J Immunol 155(11):5220–5226

    PubMed  CAS  Google Scholar 

  • Van Roosbroeck K et al (2011) JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 117(15):4056–4064

    Article  PubMed  Google Scholar 

  • Vardiman JW (2010) The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 184(1–2):16–20

    Article  PubMed  CAS  Google Scholar 

  • Verma A et al (2003) Jak family of kinases in cancer. Cancer Metastasis Rev 22(4):423–434

    Article  PubMed  CAS  Google Scholar 

  • Walters D (2006) Activating alleles of JAK3 in acute megakaryoblast…. Cancer Cell 10:65–75, PubMed result

    Article  PubMed  CAS  Google Scholar 

  • Wang W et al (2010) AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood 116(2):254–266

    Article  PubMed  CAS  Google Scholar 

  • Wernig G et al (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107(11):4274–4281

    Article  PubMed  CAS  Google Scholar 

  • Wernig G et al (2008) The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 111(7):3751–3759

    Article  PubMed  CAS  Google Scholar 

  • Xiang Z et al (2008) Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 111(9):4809–4812

    Article  PubMed  CAS  Google Scholar 

  • Xu X et al (1995) Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells. J Clin Invest 96(3):1548–1555

    Article  PubMed  CAS  Google Scholar 

  • Zhang SJ et al (2007) The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient. Int J Lab Hematol 29(1):71–72

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Molecular Medicine, Austrian Academy of Sciences, Lazarettgasse 14, 1090, Vienna, Austria

    Damla Olcaydu & Robert Kralovics

Authors
  1. Damla Olcaydu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Kralovics
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Kralovics .

Editor information

Editors and Affiliations

  1. , Max F. Perutz Laboratories, University of Vienna, Dr. Bohr-Gasse 9/4, Vienna, 1030, Austria

    Thomas Decker

  2. , Animal Breeding and Genetics, University of Vienna, Veterinärplatz 1, Vienna, 1210, Austria

    Mathias Müller

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Wien

About this chapter

Cite this chapter

Olcaydu, D., Kralovics, R. (2012). The Role of Janus Kinases in Hematopoietic Malignancies. In: Decker, T., Müller, M. (eds) Jak-Stat Signaling : From Basics to Disease. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0891-8_14

Download citation

Publish with us

Policies and ethics

Search

Navigation